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Introduction 
Kidney stones are common in industrialized countries with a lifetime risk of up to 10% [1]. 
Several studies have described a significant relationship between nephrolithiasis and 
adverse renal outcomes, including ESRD, and the need for timely and early diagnosis, and 
treatment. The pathogenesis of kidney stones is mixed, including genetic and non-genetic 
risk factors such as diet, environment, and lifestyle. Recent studies have reported a 
significant percentage of adult kidney stone patients with an underlying monogenic disease 
[2,3]. So far more than 30 genes have been identified as causative for nephrolithiasis or 
nephrocalcinosis. Transmission may be autosomal dominant, autosomal recessive or X-
linked. The majority of gene defects encode for proteins that are expressed in the kidney. 
However, several genes that are not involved directly in normal kidney function may also be 
a cause of kidney stones. Interestingly, the percentage of monogenic stone disease seems 
to be high in both children and adults, with more recessive causes found in children and 
more dominant cases in adults [3,2]. This review encompasses different genetic disorders 
that cause kidney stones and focuses on the importance of including possible underlying 
genetic causes of kidney stones in the differential diagnosis and metabolic work-up of 
recurrent kidney stone formers.  
 
 
SLC7A9/SLC3A1 (Cystinuria) 
Cystinuria is an autosomal recessive disease caused by mutations of 2 different genes, 
SLC7A9 (solute carrier family 7 member 9) and SLC3A1. Together these genes encode for 
the 2 subunits of a dibasic amino acid (cystine, ornithine, lysine, and arginine) transport 
protein located in the apical membrane of the epithelial cells lining the proximal tubule and 
small intestine [4]. The heavy subunit rBAT (SLC3a1) modifies the activity of the light subunit 
b0,bAT (SLC7a9), which is the transport channel. Mutations result in reduced renal 
reabsorption of dibasic amino acids, with high concentrations of cystine in the urine, and 
subsequent formation of cystine stones due to its low solubility at acid and normal (ca. 6.5) 
urinary pH values. To date 3 different types of cystinuria have been classified according to 
the type of mutation present: i) type A with mutations on both alleles of SLC3A1; ii) type B 
with mutations on both alleles of the SLC7A9 gene; and iii) type AB, which is very rare with 2 
mutated alleles in the same gene and a mutated allele in the other gene [5]. While SLC3A1 
heterozygous subjects have normal excretion of cystine, it is increased in SLC7A9 
heterozygotes, although not to the levels seen in type B patients; SLC7A9 heterozygous 
subjects have a mildly increased risk of forming cystine stones [6]. 
The prevalence of cystinuria depends on the geographical region and may vary from 1:2000 
in the Mediterranean to 1:100,000 in Sweden[5]. In a cohort of 272 genetically unresolved 
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children (n=106) and adults (n=166) from 268 families with nephrolithiasis or isolated 
nephrocalcinosis, mutations in SLC7a9 were described as the most common type [4]. The 
first symptoms may occur during childhood, but the median age for a first stone has been 
reported to be 26 years [4]. Male patients seem to exhibit a more aggressive disease with a 
higher number of stone episodes and an earlier age of onset. Diagnosis is generally done on 
stone analysis or finding cystine crystals in the urinary sediment. Cystinuria and other dibasic 
aminoaciduria are increased. In 24-h urine, the excretion of cystine and total dibasic amino 
acid is higher than 1300 μmol/g creatinine  and 5900 μmol/g, respectively; in B carriers levels 
are lower [6]. Recurrence rates are critical in cystinuria patients and the aim is to prevent 
recurrent stone formation by increasing the urinary solubility of cystine, and limiting its 
excretion. Preventive measures include significant hydration (>3L/day, especially overnight), 
urinary alkalinisation (an alkali ash diet or addition of oral alkali as citrate or bicarbonate), 
and reducing dietary salt intake. In addition, drugs that can reduce cystine to the more 
soluble cysteine, such as D-penicillamine, tiopronin, or captopril, can also be tried [5]. 
 
APRT  
The enzyme adenine phosphoribosyltransferase (APRT), coded by the APRT gene located 
on chromosome 16q24, catalyzes the conversion of adenine to adenosine monophosphate. 
In patients with APRT deficiency, adenosine is metabolized by xanthine oxidase to 2,8-
dihydroxyadenine (DHA), which is insoluble at physiological urine pH. Affected patients 
develop crystalluria and recurrent kidney stones; progressive loss of renal function has also 
been described [7]. The inheritance of the disease is autosomal recessive and up to now 24 
different mutations have been described. The diagnosis can be made with the finding of the 
characteristic DHA crystals in the urine (round and reddish-brown with a central Maltese 
cross pattern), or with infrared spectrophotometry or x-ray crystallography analysis of the 
stones. Treatment with dietary purine restriction and allopurinol, a xanthine oxidase inhibitor, 
has been reported to be effective in preventing new stone formation and progressive renal 
impairment [8]. 
 
Inherited renal tubular acidoses 
Inherited distal renal tubular acidosis 
Distal renal tubular acidosis (dRTA) is characterized by an inappropriately alkaline urinary pH 
in the clinical context of a non-anion gap metabolic acidosis, and is caused by defective 
distal urinary acidification [9]. To date, mutations in 3 different genes have been described to 
be causative for inherited dRTA: ATP6V1B1, ATP6V0a4 and SLC4A1. SLC4A1 mutations 
usually cause autosomal dominant dRTA, while ATP6V1B1 and ATP6V0a4 cause recessive 
dRTA [9]. Clinical signs and symptoms can vary among patients, depending on the 
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underlying gene mutation, and vary from a mild metabolic acidosis with incidental detection 
of kidney stones to severe manifestations with failure to thrive and growth retardation in 
children, rickets/osteomalacia, severe metabolic acidosis and nephrocalcinosis [9]. Typically, 
kidney stones in dRTA are of the calcium phosphate type due to: i) release of calcium and 
phosphate from bone due to buffering acidosis, and consequent hypercalciuria; and ii) 
calcium phosphate precipitation in urine due to an alkaline pH. Distal RTA should be 
considered in children and young adults with nephrocalcinosis or with recurrent kidney stone 
formation, particularly if 100% apatite stones accompany metabolic acidosis or if there is a 
family history, especially also of deafness or impaired hearing. 
ATP6V1B1 and ATP6V0a4 
The vacuolar H+-ATPase is crucial for urinary acidification and consists of two domains with 
at least 14 subunits in humans: i) the membrane-bound V0 domain, which is responsible for 
proton transfer; and ii) the cytosolic catalytic V1 domain that is necessary for hydrolysis of 
ATP[9]. ATP6V1B1 and ATP6V0A4 mutations affect 2 different subunits of the vacuolar H+-
ATPase, the B1 and a4 subunits, respectively. The B1 subunit is expressed in type A 
intercalated cells, as well as in the thick ascending limb of the loop of Henle [10]. In addition 
to type A intercalated cells, the a4 subunit is also expressed in proximal tubule cells and loop 
of Henle. Homozygous or compound heterozygous mutations in these subunits result in 
dRTA and a single-nucleotide polymorphism (SNP, c.481G>A; p.E161K) in ATP6V1B1 has 
been reported to increase the risk of developing nephrolithiasis and nephrocalcinosis when 
compared with unaffected controls [11]. Clinically, recessive dRTA usually manifests during 
infancy or childhood. The majority of patients develop progressive sensorineural deafness 
and some patients may also show abnormal widening of the vestibular aqueduct [12]. 
Nephrolithiasis and nephrocalcinosis are very common and may be evident from early 
childhood. Recent data indicate differences in phenotype depending on the affected subunit. 
Experiments in a4 deficient mice have described proximal tubular dysfunction with impaired 
endocytosis, low molecular weight (tubular) proteinuria (LMWP), phosphaturia and 
accumulation of lysosomal material in proximal tubule cells [13]. These novel findings may 
indicate an important contributory role of the proximal tubule in the pathogenesis of dRTA. 
Treatment consists mainly of alkali supplementation; however, no beneficial effect of alkali 
has been demonstrated for nephrocalcinosis or deafness [14]. 
SLC4A1 
SLC4A1 encodes the chloride bicarbonate exchanger AE1 (Anion exchanger 1, Band 3) 
located on the basolateral membrane of type A intercalated cells. AE1 exchanges 
intracellular bicarbonate for chloride, transferring newly generated bicarbonate into blood 
[15]. In Caucasians AE1 mutations causing dRTA are mainly autosomal dominant. 
Interestingly, AE1 is also expressed in erythrocytes, and autosomal recessive mutations in 
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AE1 have been shown to cause Southeast Asian Ovalocytosis, Hereditary Spherocytosis, 
and dRTA [15]. However, the disease manifestation is usually renal or haematological, and in 
only rare cases patients can present with a combined renal and haematological phenotype. 
Interestingly, the haematological phenotype is improved by alkali therapy [16].  
 
Inherited combined proximal and distal renal tubular acidosis 
Carbonic anhydrase II 
Carbonic anhydrases (CA) are zinc metalloenzymes that catalyze the bi-directional 
interconversion of carbon dioxide and water to HCO3- and H+. Several isoforms of CA are 
expressed in the human kidney: CA II is the most abundant kidney isoform and the only 
isoform present in osteoclasts [17]. CA II is expressed in all nephron segments and 
autosomal recessive mutations result in a combined proximal and distal form of RTA. The 
prevalence of CA II deficiency is very high in Arabic patients due to a splice junction mutation 
[18]. As well as RTA, the clinical phenotype can include osteopetrosis, cerebral calcification, 
facial dysmorphism with low set ears, hypertelorism, and a depressed nasal bridge plus mild 
conductive hearing loss [17]. RTA is characterized by defective urinary acidification and 
additional urinary bicarbonate loss, resulting in kidney stone formation or nephrocalcinosis 
[19]. In contrast, mutations in SLC4A4 encoding for NBCe1 (the proximal tubule basolateral 
electrogenic sodium bicarbonate co-transporter) cause isolated proximal RTA and ocular 
abnormalities without nephrolithiasis or nephrocalcinosis [20]. 
 
  
Mutations of renal sodium phosphate co-transporters 
SLC34A3 (Hereditary Hypophosphatemic Rickets with Hypercalciuria, HHRH) 
SLC34A3 (solute carrier family 34, member 3) encodes the sodium-dependent phosphate 
co-transporter 2c (NPT2c), which is located in the proximal tubule and mediates phosphate 
reabsorption across the apical brush border membrane [21]. Homozygous or compound 
heterozygous mutations of SLC34A3 cause hereditary hypophosphatemic rickets with 
hypercalciuria (HHRH), which is characterized by hypophosphatemia from increased renal 
phosphate losses, hypercalciuria, elevated 1,25(OH)2-vitamin D levels, and rickets [22,23]. A 
genetic diagnosis of this form of rickets, which is vitamin D-resistant, is important so as to 
avoid unnecessary treatment with vitamin D, which risks causing hypercalcaemia, 
hypercalciuria, nephrocalcinosis, renal stones and renal failure. 
A recent study of 133 individuals from 27 kindreds, with known and novel mutations of 
SLC34A3 has found a significantly increased risk for nephrolithiasis or nephrocalcinosis in 
homozygous mutants when compared with their healthy relatives carrying the wild type allele 
or the general population (46% vs. 6% vs. 5.64%) [24]. Also, a small genome-wide 
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association study (GWAS) identified SLC34a3 as a locus for hypercalciuric kidney stone 
disease [25]. Heterozygous SLC34A3 mutation carriers can present with isolated 
hypercalciuria similar to patients with so-called idiopathic hypercalciuria (IH). However, the 
biological and clinical significance of heterozygous mutations, which are quite frequent, is still 
unknown. Thus, future studies will be necessary to understand the contribution, if any, of 
heterozygous mutations to the risk of kidney stone disease. Treatment of HHRH with oral 
phosphate can reverse hypophosphatemia, hypercalciuria, and cure bone disease, but can 
overshoot and stimulate PTH secretion, which needs to be monitored. 
 
SLC34A1 
SLC34A1 (solute carrier family 34, member 1) encodes for the sodium-dependent phosphate 
co-transporter 2a (NPT2a), which is expressed mainly in the kidney proximal tubule, and like 
SLC34A3 is responsible for renal phosphate reabsorption [21]. Only a few patients have 
been reported with mutations in the SLC34A1 gene presenting with nephrolithiasis and 
hypophosphatemia caused by a renal phosphate leak (Hypophosphatemic 
nephrolithiasis/osteopetrosis-1 and Fanconi renotubular syndrome-2) [26-28]. However, 
experiments using the reported NPT2a mutations (Single nucleotide changes resulting in 
missense mutations -A48F and V147M- with a dominant effect) expressed in Xenopus 
oocytes and renal OK cells could not confirm any changes in transporter expression or 
substrate affinity, and only showed lower transport activity [29]. Furthermore, polymorphisms 
in the SLC34A1 gene seem to be quite frequent without affecting renal phosphate excretion 
in many individuals [30]. Conversely, expression of an in-frame duplication of 21 bp in 
Xenopus oocytes and renal OK cells resulted in elimination of phosphate transport capacity. 
This mutation was previously reported in siblings from a consanguineous family suffering 
from hypophosphatemia and hypercalciuria due to a secondary increase in 1,25-(OH)2-Vit. D 
levels [28]. Furthermore, a very recent study investigated relatives of a 16.5 year-old boy with 
nephrocalcinosis and chronic kidney disease (CKD), but with no bone disease. Genetic 
testing revealed a homozygous missense mutation in SLC34A1[31]. However, out of 6 
heterozygous carriers of this mutation, only 2 presented with kidney stones, and one 
individual with kidney stones carried two wild-type SLC34A1 alleles. Thus, the biological and 
clinical significance of SLC34A1 mutations (heterozygous or homozygous) in the context of 
kidney stone disease remains uncertain.   
 
CYP24A1 (Idiopathic Infantile Hypercalcaemia) 
1,25-(OH)2-24-Hydroxylase (CYP24A1) is a mitochondrial cytochrome P-450 enzyme mainly 
present in kidney and intestine. CYP24A1 protects against Vitamin D toxicity by inactivating 
both, 25-OH- (calcidiol) and 1,25-(OH)2-Vit. D (calcitriol). Homozygous inactivating mutations 
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of CYP24A1 gene lead to increased 1,25-(OH)2-Vit. D and cause idiopathic infantile 
hypercalcemia (Lightwood syndrome), a rare autosomal recessive disease manifesting since 
the first months of life and characterized by severe hypercalcemia, low PTH, 
nephrocalcinosis, nephrolithiasis and renal failure [32].  
Recently described cases have expanded the phenotypic spectrum of disorders due to loss 
of function mutations of CYP24A1 to cases with recurrent nephrolithiasis starting in early 
adulthood, with hypercalciuria, and serum calcium mildly or intermittently increased. Carriers 
of the mutated CYP24A1 gene may have high or borderline elevated 1,25-(OH)2-Vit. D 
levels, hypercalciuria, and kidney stones [32-35]. In addition, the frequency of homozygosity 
for mutated CYP24A1 in the general population was predicted to be 4-20% according to 
dbSNP (NCBI-Single Nucleotide Polymorphism Database) suggesting a causative role for 
CYP24A1 in the formation of calcium-containing renal stones in a significant proportion of the 
population [36]. Interestingly some data even suggest that patients with mutations in 
CYP24A1 can develop CKD [32,33]. Mutations in CYP24A1 should be considered in patients 
with kidney stones and idiopathic hypercalciuria, especially if hypercalcemia with suppressed 
PTH is noted. The disease is treated by reducing calcium load (low calcium diet, low vitamin 
D intake and oral sodium cellulose phosphate), and -in severe cases- with ketoconazole to 
inhibit 25-OH-Vitamin D-1α-hydroxylase.  
 
 
Disorders of the Calcium Sensing Receptor  
Familial hypocalciuric hypercalcemia (FHH, familial benign hypercalcemia) is an autosomal-
dominant disease caused by mutations in 3 different genes: i) inactivating mutations of the 
calcium sensing receptor (CASR) gene (FHH type 1, most common type); ii) loss-of-function 
mutations of AP2S1 that encodes the adaptor-related protein complex 2, σ-2 subunit (FHH 
type 2); and iii) GNA11 that encodes the Gα11 protein (FHH type 3) [37]. FHH is characterized 
by mild hypercalcemia, low or normal PTH levels, a urinary calcium to creatinine ratio 
(CCCR) <0.01, and a benign clinical course. Recent studies have highlighted the importance 
of FHH as a differential diagnosis for primary hyperparathyroidism (pHPT) with significant 
overlap in the phenotype [38,37]. Interestingly, a recent study from Italy has described the 
prevalence of kidney stones in up to 3 out of 13 (23%) patients with CASR mutations or 
polymorphisms previously selected for genetic testing based on clinical and biochemical 
feature compatible with FHH [38]. It is difficult to explain the lithogenic role of loss of function 
mutations of the CASR gene especially in view of the associated hypocalciuria. Confirmation 
of the association with nephrolithiasis in larger cohorts is needed. 
Activating mutations of the gene for the CASR extracellular domain lead to autosomal 
dominant hypocalcemia with hypercalciuria [39]. Clinical manifestations mirror 
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hypoparathyroidism, with mild, asymptomatic hypocalcemia and marginally high 
phosphatemia but with low-normal serum PTH. Hypercalciuria results from inhibition by 
CASR of both active and passive calcium reabsorption in the thick ascending limb of Henle’s 
loop. However, this is a very rare condition and to our knowledge the association with renal 
stones has not been reported. 
Nevertheless, other interesting studies suggest a role of the CASR gene in nephrolithiasis. A 
GWAS of 106,856 Icelanders, including 2,636 individuals with a history of kidney stones, 
identified sequence variants in CASR and a suggestive association with kidney stones [40]. 
These variations in intron 1 may decrease the transcriptional activity of the CASR gene 
promoter 1 and the expression of the CaSR protein in the kidney, as previously described for 
two single nucleotide polymorphisms in normocitraturic stone formers by Vezzoli et al. [41], 
and thereby change the response of the CaSR to extracellular calcium. Consequently, 
impaired distal urinary acidification and reduced dilution capacity may result in stone 
formation [41,38,42].  
 
SLC22A12/SLC2A9 (Hereditary renal hypouricemia, RHUC) 
Hereditary renal hypouricemia is caused by recessive mutations in two different genes, 
SLC22A1 and SLC2A9, encoding the proximal renal tubular urate transporter 1, URAT1, and 
what was originally thought to be a glucose transporter, GLUT9, respectively [43]. However, 
GLUT9 belongs to the family of GLUT proteins that mediate transepithelial transport of 
monosaccharides and represents the only member that also and preferentially transports 
urate. Transcellular urate transport is via the apical reabsorption of urate by URAT1, followed 
by basolateral urate exit via GLUT9. Loss-of-function mutations in SLC22A1 affect the 
majority of patients with RHUC. The phenotype is variable and includes asymptomatic 
patients and patients with uric acid nephrolithiasis or exercise-induced acute kidney injury 
(AKI). Patients with homozygous GLUT9 mutations present with more pronounced 
hypouricemia and are more prone to nephrolithiasis, and AKI after exercise. However, the 
underlying mechanism for AKI is still unknown; mechanisms such as urate nephropathy or 
increased oxidative stress during exercise with renovascular spasm and vasoconstriction 
leading to renal tissue damage have been proposed [44,43]. Typical histological and imaging 
findings of repeated vasoconstriction in kidney biopsies from patients with GLUT9 mutations 
are supportive of the oxidative stress/vasoconstriction hypothesis [45,43]. Therapy consists 
of adequate fluid intake during exercise and, interestingly, allopurinol, which has been 
reported to be beneficial by reducing the load of filtered urate [46], but may also have 
something to do with its intrinsic antioxidant properties. Better-targeted therapies for these 
patients are needed, since they are at increased risk of developing ESRD as a result of 
recurrent episodes of AKI. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 CLCN5/OCRL1 (Dent Disease and Lowe Syndrome) 
X-linked mutations in CLCN5 cause Dent disease (or Dent disease type 1) that is 
characterized by low molecular weight proteinuria, hypercalciuria, nephrolithiasis and 
nephrocalcinosis with renal impairment progressing to ESRD in many patients [47]. Some 
patients may also present with hypophosphatemic rickets or osteomalacia, and even a more 
generalized proximal tubular dysfunction (e.g., Fanconi syndrome). CLCN5 encodes for the 
renal chloride/proton exchanger ClC-5 and plays an important role in receptor-mediated 
endocytosis [48]. The cause of ESRD in Dent disease is not fully understood, and is not 
inevitable and, surprisingly, does not correlate with the degree of nephrocalcinosis present. 
Interestingly, kidney biopsies of asymptomatic patients show a focal segmental 
glomeruloscerosis (FSGS) pattern in a substantial number [49]. Female carriers can rarely 
present with the same phenotypic characteristics as males, but only one female case has 
been reported to develop ESRD [50].  
Mutations in OCRL1 cause Lowe syndrome (or Dent disease type 2), a disease with a similar 
renal phenotype to Dent disease 1, but with additional multi-system clinical manifestations, 
including mental retardation, cataracts, and epilepsy. OCRL1 encodes for the inositol 
polyphosphate 5-phosphatase OCRL-1 and is involved in several cellular processes 
including control of endocytic recycling, endosome-to-Golgi transport, and early endocytosis. 
Recently, OCRL1 has also been described to be crucial for the response of lysosomes to the 
autophagic cargo [51]. Thus, defective OCRL1 leading to impaired autophagic flux may 
underlie progressive kidney dysfunction in Lowe syndrome. Diagnosis is based on the 
presence of low-molecular weight proteinuria, hypercalciuria and at least one of the following: 
nephrocalcinosis, kidney stones, hypophosphatmia, microhematuria, and renal failure. The 
diagnosis is supported by a history of X-linked inheritance of nephrolithiasis and renal failure 
and is confirmed by the identification of mutations in either the CLCN5 gene (Dent disease 1) 
or the ORCL1 gene (Dent disease 2). Thiazide diuretics may be effective in treating 
hypercalciuria[52]. In ClC-5-deficient mouse model a high citrate diet seems to delay 
progression of renal disease [53]. 
 
CLDN14 
CLDN14 encodes for Claudin-14, a member of the claudin family that is expressed at 
epithelial tight junctions in the thick ascending limb of the loop of Henle [54]. Claudin-14 is 
involved in the paracellular transport of ions and small solutes, and variants in CLDN14 have 
been associated with kidney stones and reduced bone mineral density (BMD)[55]. 
Furthermore, the CLDN14 SNP rs113831133 has been reported to be associated with lower 
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urinary calcium excretion, suggesting that Claudin-14 is involved in controlling renal calcium 
excretion [56]. Interestingly, a second variant, rs219780, which is very common in the 
general population, has been identified as a risk variant with 1.64x greater risk for kidney 
stone formation [55]. However, genetic validation studies in larger sample sets will be 
necessary to confirm the role of Claudin-14. 
 
CLDN16/CLDN19 (Familial hypomagnesemia with hypercalciuria and 
nephrocalcinosis, FHHNC) 
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an 
autosomal recessive disease caused by mutations in CLDN16 or CLDN19. Claudin-16 and -
19 are expressed in the thick ascending limb of the loop of Henle and mediate the 
paracellular reabsorption of calcium and magnesium [57,58]. FHHNC patients develop CKD 
in early childhood and adolescence due, in part, to hypercalciuria, kidney stones and 
nephrocalcinosis [57]. Other disease manifestations include seizures, muscular tetany, 
failure to thrive, ocular abnormalities, increased PTH levels, recurrent urinary tract infections 
(UTI) (a likely actor in CKD progression), incomplete dRTA, and hypocitraturia [57,59]. In 
contrast to patients with Dent disease, progression to ESRD correlates with the severity of 
nephrocalcinosis and appears to be predicted by the genotype. Of note, healthy family 
members may also be significantly affected by hypercalciuria, UTI and kidney stones [59]. 
There is no effective therapy for FHHNC. Magnesium supplements are necessary to correct 
hypomagnesemia, but have not been shown to be beneficial and have no long-term effect on 
calcium excretion [59]. Treatment with thiazide diuretics can reduce calciuria in the short-
term in patients with CLDN16 mutations [60]. No treatment has been shown to delay CKD 
progression. When ESRD is reached, kidney transplantation is the treatment of choice, and 
normalises renal magnesium and calcium handling. 
 
Primary hyperoxalurias 
Primary hyperoxaluria (PH) is caused by recessive mutations in different hepatic enzymes 
resulting in endogenous accumulation of oxalate with subsequent hyperoxaluria. So far, 
three different genes have been identified to cause PH, namely AGT, GRHPR, and HOGA1 
[61], although other genes encoding proteins involved in glyoxylate metabolism have been 
postulated [62]. 
AGXT (Primary hyperoxaluria type 1, PH1) 
PH1 is the most common type of primary hyperoxalurias and is caused by recessive 
mutations in the AGXT gene encoding for the liver-specific peroxisomal enzyme alanine 
glyoxylate aminotransferase (AGT). AGT catalyzes the transamination of glyoxylate to 
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glycine and lack of AGT or loss of activity result in over-production of oxalate and glycolate. 
More than 170 mutations have been identified to cause PH1 [61]. Interestingly, some 
mutations (Gly170Arg and Phe15Ile) have been demonstrated to be pyridoxine-sensitive, 
while other genotype-phenotype relationships have not been described as yet [63]. 
Moreover, siblings with the same genotype may present with a different clinical course[63]. 
Renal manifestations usually include recurrent kidney stones or nephrocalcinosis 
progressing to ESRD between 20 and 30 years of age in the majority of patients [61]. In 
addition, other organs may be involved by systemic deposition of oxalate crystals in bone, 
heart, and skin. Increased urinary excretion of oxalate (> 1 mmol/24h) with calcium oxalate 
monohydrate kidney stones and impaired renal function are highly suggestive of PH1, and 
diagnosis can be confirmed by genetic testing. Detection of oxalate crystals in kidney biopsy 
tissue or elevated urinary glycolate levels are also indicative of PH1 [61]. Supportive 
treatment includes high oral fluid intake, alkali citrate, and pyridoxine in a subset of patients 
with pyridoxine-sensitive mutations. As to renal replacement therapy, in adults hemodialysis 
should be initiated in ESRD or in CKD if there are signs of systemic oxalosis [61]. Since there 
is an increased risk of systemic oxalosis at the start of renal replacement therapy, daily 
dialysis sessions are recommended to increase dialysis efficiency and maximise oxalate 
removal. Also, a combination of peritoneal dialysis with hemodialysis may be considered in 
cases with inadequate oxalate removal (plasma oxalate levels > 30 μmol/L at the end of 
each dialysis session) or with a high risk of systemic oxalosis [61]. Currently, the only 
curative therapy for PH1 is pre-emptive liver transplantation or sequential or combined liver 
and kidney transplantation, the latter being the preferred method in the majority of the 
patients. Fortunately, there is some light at the end of the tunnel with several new therapeutic 
developments in the pipeline, including gene therapy, hepatocyte transplantation, substrate 
reduction therapy via RNAi, and AGT chaperone treatment [64,61].  
 
GRHPR (Primary hyperoxaluria type 2, PH2) 
PH2 is caused by recessive mutations in the GRHPR gene encoding for the ubiquitously 
expressed glyoxylate reductase/hydroxypyruvate reductase (GRHPR) enzyme [61]. GRHPR 
is primarily expressed in the liver and mutations result in over-production of both oxalate and 
L-glyceric acid. PH2 patients present with recurrent urolithiasis, but in contrast to PH1, their 
clinical course is less severe with only a minority of patients developing CKD and ESRD. In 
addition to increased urinary oxalate levels, L-glycerate excretion may also be increased in 
PH2 patients [61]. As for PH1 and especially after exclusion of PH1, genetic testing for PH2 
should be performed to confirm diagnosis. Conservative treatment is similar to PH2, except 
for pyridoxine administration (unresponsive). The current treatment of choice is isolated 
kidney transplantation; however, the less severe course of PH2 means that only a few 
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patients have required transplantation, although immediate recurrence with subsequent rapid 
graft loss has been reported in one patient [65,64,61,66].  
HOGA1 (Primary hyperoxaluria type 3, PH3) 
Mutations in the liver-specific mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA) 
enzyme have been described recently to cause PH3 [61]. HOGA plays an important role in 
hydroxyproline metabolism and is thought to generate excess oxalate; however, the exact 
mechanism of increased oxalate production in PH3 has not been completely elucidated. Of 
the PH subtypes, PH3 has the mildest phenotype and patients typically present with 
recurrent kidney stones early in life. Interestingly, in addition to hyperoxaluria, significant 
hypercalciuria and increased uric acid excretion have been observed in PH3 patients [67,68]. 
Interestingly, the clinical course can improve over time and no cases of PH3 patients with 
ESRD have been reported [69]. The presence of HOG precursors, in addition to 
hyperoxaluria and hypercalciuria, is suggestive of PH3, which can be confirmed by genetic 
testing. To date there are no specific treatment recommendations -though a low animal 
protein diet has been suggested- and no guidelines for renal replacement therapy or 
transplantation in PH3.  
 
The ‘newest kid on the block’: SLC26a1 
SLC26A1 (SAT1, solute carrier family 26 member 1) was initially cloned as a sulphate 
transporter in the liver and functions as an electroneutral anion exchanger that exchanges 
sulphate for bicarbonate or oxalate, as well as oxalate for bicarbonate [2]. In the kidney 
SlC26a1 is located in the proximal tubule and Slc26a1 deficient mice are hyposulphatemic, 
with increased urinary sulphate excretion, and calcium oxalate kidney stones if hyperoxaluria 
is also present. A recent study has identified recessive mutations in SLC26A1 in 2 unrelated 
individuals with calcium oxalate kidney stones [2]. Experimental data have shown that 
mutations in SLC26A1 result in decreased transporter activity and nephrolithiasis. Notably, 
another member of the SLC26 family, namely SLC26A6 has also recently been described to 
be potentially associated with calcium oxalate kidney stones [70]. These data are supported 
by previous animal studies that demonstrated that mice deficient for SLC26A6 suffer from 
hyperoxaluria with a high incidence of calcium oxalate urolithiasis [71]. 
 
Conclusion 
There is no short cut to diagnosing genetic forms of nephrolithiasis. It is still crucial to take a 
family history and thoroughly investigate patients for the clinical manifestations of 
inherited disorders. Pointers to inherited disease in renal stone patients are many, for 
example, early age of onset, family cases, consanguineous parents, highly-active and 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
recurrent stone disease, associated nephrocalcinosis, renal hyperechogenicity, associated 
tubular dysfunction and related manifestations (short stature, growth retardation, polyuria, 
bone disorders), renal failure and extra-renal manifestations such as sensorineural hearing 
defects, ocular abnormalities, and neurological disorders [72]. 
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Table 1: Summary of genes associated with kidney stones and disease characteristics 
Gene Disease Typical laboratory findings Typical clinical features Treatment 
SLC7a9 
SLC3a1 
Cystinuria Increased urinary cystine 
excretion or excretion of dibasic 
amino acids 
Cystine stones, nephrocalcinosis Hydration, urinary alkalinization, 
salt restriction, drugs that reduce 
cystine to cysteine, such as D-
penicillamine, tiopronin, or captopril 
APRT  DHA crystals in the urine (round 
and reddish-brown with a central 
Maltese cross pattern) 
crystalluria and recurrent kidney 
stones; progressive loss of renal 
function 
Dietary purine restriction, 
allopurinol 
ATP6V0a4 
ATP6V1B1 
 
Autosomal recessive 
dRTA 
Non-anion gap metabolic 
acidosis, alkaline urine pH, 
hypokalemia, hypercalciuria 
Calcium phosphate stones, 
nephrocalcinosis, sensorineural 
hearing loss, failure to thrive, 
rickets, additional proximal tubular 
dysfunction in patients with 
ATP6V0a4 mutations 
Alkali therapy with potassium 
citrate and/or sodium bicarbonate 
SLC4a1 Autosomal dominant 
dRTA 
Non-anion gap metabolic 
acidosis, alkaline urine pH, 
hypokalemia, hypercalciuria 
Nephrocalcinosis, autosomal 
recessive mutations cause 
Southeast Asian Ovalocytosis, 
Hereditary Spherocytosis, and 
dRTA 
Alkali therapy with potassium 
citrate and/or sodium bicarbonate 
CAII Proximal and distal renal 
tubular acidosis 
Non-anion gap metabolic 
acidosis, bicarbonaturia 
Nephrocalcinosis, kidney stones, 
osteopetrosis, cerebral calcification, 
mental retardation, facial 
dysmorphism and mild conductive 
hearing loss 
Alkali therapy with potassium 
citrate and/or sodium bicarbonate 
SLC34a1 Hypophosphatemic 
nephrolithiasis/osteopetr
osis-1 and Fanconi 
renotubular syndrome-2 
Hypophosphatemia, 
hyperphosphaturia, 
hypercalciuria, elevated 
1,25(OH)2-vitamin D levels 
Nephrolithiasis, osteopetrosis, 
nephrocalcinosis, potentially CKD 
Phosphate supplementation 
Table
SLC34a3 HHRH Hypophosphatemia, 
hyperphosphaturia, 
hypercalciuria, elevated 
1,25(OH)2-vitamin D levels 
Nephrolithiasis, nephrocalcinosis, 
rickets 
Phosphate supplementation 
CYP24a1 Idiopathic infantile 
hypercalcemia 
Hypercalcemia, elevated 1,25-
(OH)2-Vit. D levels, 
hypercalciuria 
Nephrolithiasis, nephrocalcinosis, 
failure to thrive, disease can be 
unmasked after vitamin D (calcidiol) 
administration, patients may 
develop CKD 
Diuretics, corticosteroids, 
bisphosphonates, vitamin D 
withdrawal 
CasR 
AP2S1 
GNA11 
FHH Mild hypercalcemia, normal to 
slightly elevated PTH levels, 
CCCR < 0.01 
May mimick primary 
hyperparathyroidism 
Adequate fluid intake 
SLC22a12 
SLC2a9 
RHUC Hypouricemia, hyperuricosuria Nephrolithiasis, exercise-induced 
AKI, patients may develop ESRD 
after recurrent AKIs 
Adequate fluid intake during 
exercise, allopurinol 
CLCN5 
 
Dent disease 
 
LMWP, Fanconi syndrome Nephrolithiasis, nephrocalcinosis, 
CKD with progression to ESRD 
Isolated kidney transplantation 
OCRL1 Lowe syndrome LMWP, Fanconi syndrome Nephrolithiasis, nephrocalcinosis, 
CKD with progression to ESRD, 
mental retardation, cataract, and 
epilepsy 
Isolated kidney transplantation 
CLDN16 
CLDN19 
FHHNC Hypomagnesemia, 
hypercalciuria, increased PTH 
levels, incomplete distal renal 
tubular acidosis, hypocitraturia 
Nephrocalcinosis progressing to 
CKD/ESRD, seizures, muscular 
tetany, failure to thrive, ocular 
abnormalities, recurrent UTI 
Isolated kidney transplantation 
CLDN14  Hypercalciuria  Nephrolithiasis, reduced BMD No specific recommendations 
available yet 
AGXT PH1 Hyperoxaluria, increased urinary 
excretion of glycolate 
Calcium oxalate monohydrate 
stones, development of CKD with 
progression to ESRD in the second 
Hydration, urinary alkalinization, 
pyridoxine in selected patients, 
combined liver and kidney 
or third decade of life, risk of 
systemic oxalosis involving bone, 
skin, heart etc.  
transplantation  
GRHPR PH2 Hyperoxaluria, increased urinary 
excretion of L-glyceric acid 
Calcium oxalate monohydrate 
stones, few cases reported with 
CKD/ESRD 
Hydration, urinary alkalinization, 
isolated kidney transplantation 
HOGA1 PH3 Hyperoxaluria, hypercalciuria, 
hyperuricosuria 
Calcium oxalate monohydrate 
stones mild clinical course 
 
SLC26a1  Hyperoxaluria Calcium oxalate stones, 
nephrocalcinosis 
No specific recommendations 
available yet 
 
